Treating Stage IV Right-Sided CRC Beyond Progression
Watch
Frontline Therapy for Stage IV Right-Sided CRC
Molecular Testing and Tumor Sidedness in CRC
Diagnosing and Managing Stage IV Right-Sided CRC
A 75-Year-Old Man With Right-Sided mCRC
Future Developments & Screening Recommendations in CRC
Treatment Strategies for Left-Sided KRAS-Mutated CRC
Considerations for Managing an Atypical Patient With CRC
KRAS-Mutated Metastatic CRC
Next Steps for CAR T Cells in B-Cell Lymphomas
Victor A. Chow, MD, discusses the next steps for chimeric antigen receptor T-cell therapy in patients with B-cell lymphomas.
Managing Immunotherapy Toxicities in Melanoma
Michael A. Postow, MD, shares advice to community oncologists on managing the side effects of immunotherapy in patients with melanoma.
Looking to the Future of PARP Inhibitors in CRPC
Tanya Dorff, MD, discusses recent data with olaparib (Lynparza) in castration-resistant prostate cancer and the future role of PARP inhibitors in this disease.<br />
Assessing the Role of Darolutamide in CRPC
Raoul S. Concepcion, MD, FACS, director, Comprehensive Prostate Center, discusses takeaways from the ARAMIS study of darolutamide in patients with nonmetastatic castration-resistant prostate cancer.
NSCLC Stage III Unmet Needs and Practical Advice
Durvalumab Following Chemoradiotherapy and Surgery
PACIFIC Trial Implications Concerning NSCLC Mutations
Implications of Durvalumab Following PACIFIC Update
The Impact of the PACIFIC Trial and Updated Analysis
The Unprecedented Data of Next-Generation Sequencing
Immune Checkpoint Therapy Overview for Stage III NSCLC
Treatment Options for Stage III Unresectable NSCLC After Chemoradiotherapy
Lung Cancer
Safety Findings for Axi-Cel in Patients With DLBCL
Brian T. Hill, MD, PhD, discusses the safety findings from the ZUMA-1 trial investigating axicabtagene ciloleucel (KTE-C19, axi-cel) in patients with diffuse large B-cell lymphoma.
Expert Discusses Treatment Options for HCC According to Disease Stage
Josep M. Llovet, MD, PhD, discussed the available treatment options for patients with hepatocellular carcinoma.
Key Takeaway Points in Phase III ALCYONE Trial for Multiple Myeloma
<br /> ​Maria-Victoria Mateos, MD, PhD, discusses the key takeaways from the findings from the phase III ALCYONE trial for patients with multiple myeloma.
Key Takeaways for Neratinib Plus T-DM1 Combination in Breast Cancer
Jame Abraham, MD, discusses the key takeaways from the phase Ib study of trastuzumab emtansine in combination with neratinib in patients with HER2-positive breast cancer.
Expert Highlights Areas of Research in MCL
Krish Patel, MD, discusses the areas of research he finds particularly interesting for the treatment of patients with mantle cell lymphoma.
Emerging Themes in Targeted Therapy Research for CLL
John F. Seymour, MBBS, PhD, discusses some emerging themes from recent research for targeted therapies as treatment of patients with chronic lymphocytic leukemia.
Expert Explains the Greatest Challenge in Treating Patients With MDS and AML
Christopher R. Cogle, MD, a professor of medicine at the University of Florida, discusses the greatest challenge in treating patients with myelodysplastic syndromes and acute myeloid leukemia.
Updates in the Treatment Landscape of AML
Eunice Wang, MD, discusses the new treatment era for patients with acute myeloid leukemia after the approval of 3 new treatment regimens at the end of 2018.
Incorporating Immunotherapy in the Treatment of Early-Stage Bladder Cancer
Arjun V. Balar, MD, discusses a few approaches for incorporating immunotherapy treatments into the frontline for patients with bladder cancer.